BCHE and Alzheimer disease: This was additionally supported by the fact that the monocarbamate derivative of bambuterol, released after the decarbamylation of cholinesterase inhibited by bambuterol, also inhibits cholinesterases [22] which enables the prolonged action of bambuterol as an AD drug targeting BChE.